Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Ndjeka

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Nature Medicine|January 10, 2023
The 1/4/6x24 campaign to cure tuberculosis quicklyLindsay McKenna, Mike Frick, Ketholelie Angami, et al.
The European Respiratory Journal|October 27, 2018
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimenNorbert Ndjeka, Kathryn Schnippel, Iqbal Master, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 1, 2023
A cohort study of post-COVID-19 condition across the Beta, Delta, and Omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participantsWaasila Jassat, Caroline Mudara, Caroline Vika, et al.
American Journal of Respiratory and Critical Care Medicine|February 17, 2022
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)Aliasgar Esmail, Suzette Oelofse, Carl Lombard, et al.
The Lancet. Respiratory Medicine|November 2, 2025
Climate change and tuberculosis: an analytical frameworkMatthew J Saunders, Delia Boccia, Palwasha Y Khan, et al.
The Lancet. Infectious Diseases|November 15, 2021
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal studyNazir Ahmed Ismail, Shaheed Vally Omar, Harry Moultrie, et al.
Medrxiv : the Preprint Server for Health Sciences|March 27, 2026
Comparative effectiveness of three linezolid management strategies for peripheral neuropathy during multidrug- or rifampicin-resistant tuberculosis treatmentMatthew L Romo, Allison LaHood, Carole D Mitnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 12, 2026
Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulationMatthew Romo, Allison LaHood, Carole D Mitnick, et al.
The European Respiratory Journal|December 22, 2019
Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosisSyed Abidi, Jay Achar, Mourtala Mohamed Assao Neino, et al.
Bulletin of the World Health Organization|July 29, 2024
Target regimen profiles for tuberculosis treatmentChristian Lienhardt, Kelly E Dooley, Payam Nahid, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Nature Medicine|January 10, 2023
The 1/4/6x24 campaign to cure tuberculosis quicklyLindsay McKenna, Mike Frick, Ketholelie Angami, et al.
The European Respiratory Journal|October 27, 2018
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimenNorbert Ndjeka, Kathryn Schnippel, Iqbal Master, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 1, 2023
A cohort study of post-COVID-19 condition across the Beta, Delta, and Omicron waves in South Africa: 6-month follow-up of hospitalized and nonhospitalized participantsWaasila Jassat, Caroline Mudara, Caroline Vika, et al.
American Journal of Respiratory and Critical Care Medicine|February 17, 2022
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)Aliasgar Esmail, Suzette Oelofse, Carl Lombard, et al.
The Lancet. Respiratory Medicine|November 2, 2025
Climate change and tuberculosis: an analytical frameworkMatthew J Saunders, Delia Boccia, Palwasha Y Khan, et al.
The Lancet. Infectious Diseases|November 15, 2021
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal studyNazir Ahmed Ismail, Shaheed Vally Omar, Harry Moultrie, et al.
Medrxiv : the Preprint Server for Health Sciences|March 27, 2026
Comparative effectiveness of three linezolid management strategies for peripheral neuropathy during multidrug- or rifampicin-resistant tuberculosis treatmentMatthew L Romo, Allison LaHood, Carole D Mitnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 12, 2026
Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulationMatthew Romo, Allison LaHood, Carole D Mitnick, et al.
The European Respiratory Journal|December 22, 2019
Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosisSyed Abidi, Jay Achar, Mourtala Mohamed Assao Neino, et al.
Bulletin of the World Health Organization|July 29, 2024
Target regimen profiles for tuberculosis treatmentChristian Lienhardt, Kelly E Dooley, Payam Nahid, et al.
Pageof 6